The catalogue carries three named combinations, and one of the names means two different things. Glow Mix and Klow Blend are single vials holding three and four compounds respectively. "Wolverine" is used both for a single-vial blend of two compounds and for a bundle of three separate vials. Knowing exactly what is in each — and whether it arrives as one preparation or several — changes how the certificate should be read and what the experiment can vary.
What is in each
| Name | Format | Contents |
|---|---|---|
| Glow Mix | One vial, 70 mg | GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg |
| Klow Blend | One vial, 80 mg | GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, KPV 10 mg |
| Wolverine Blend | One vial | BPC-157 and TB-500, co-formulated |
| Wolverine Bundle | Three separate vials | BPC-157 5 mg, TB-500 10 mg, Ipamorelin 5 mg |
The first three are blends in the technical sense: one lyophilised preparation containing several compounds at a ratio fixed when it was made. The fourth is not a blend at all — three products in one order, each with its own vial and its own certificate. The distinction is the whole subject of why a blend is not three vials, and the Wolverine naming puts both cases under one word.
Why are Glow and Klow built around GHK-Cu?
Because the copper complex is the component proposed to act on the extracellular matrix, and the other two are proposed to act on angiogenic signalling and on cell migration — three non-overlapping mechanisms, on the logic that a repair model involves all three. GHK-Cu makes up most of the mass in both blends, 50 mg of 70 or 80, so the vial is chemically a GHK-Cu preparation with two smaller components dissolved alongside it. That has consequences: the copper complex's sensitivities to pH, chelators and reducing agents govern the whole vial, and the blue-violet colour of the solution is GHK-Cu's, not a property of the blend.
What does KPV add in Klow that Glow lacks?
A fourth mechanism. KPV is the C-terminal tripeptide of α-MSH, retaining an anti-inflammatory literature while lacking the parent hormone's receptor activity. Adding it to the repair trio is aimed at models where inflammation and remodelling are studied together. It is also the smallest and most surface-exposed component — three residues at 10 mg in an 80 mg vial — which makes it the one most likely to be under-represented in a dilute working solution through adsorption losses.
What the certificate has to show
For a single compound, one identity confirmation and one purity figure. For a three- or four-component blend, that many of each, plus a measured ratio. A combined purity across a blend is close to meaningless: a vial could be 99% peptide and hold the components in badly wrong proportion.
The ratio is the figure to look for and the one most often absent. "1:1 as formulated" reports the recipe. A measured ratio on the finished material reports the product, and the two differ because each component carries its own water and counter-ion burden and dissolves at its own rate during formulation. Reading the panels for what they prove matters more here than anywhere else in the catalogue.
Can the method even resolve four components?
It has to, and it is not automatic. Two compounds of similar hydrophobicity can co-elute on a reversed-phase column, and a chromatogram of a four-component blend showing three peaks has either merged two components or missed one. Four resolved peaks are the minimum evidence that four purity figures are real. The trace shows whether the separation was achieved; the numbers alone do not.
When is the bundle the better choice?
Whenever the ratio is a variable. The bundle's three vials each carry their own certificate and can be combined at any proportion, changed between runs, or used singly. The blends fix the ratio at manufacture and remove that freedom in exchange for removing two or three transfer steps. If the work needs BPC-157 and TB-500 at one settled proportion, the co-formulated vial removes an error source. If the work is asking what the proportion should be, the blend is the wrong object and the bundle — or the separate compounds — is the right one. The bundle's ipamorelin, incidentally, is not a repair compound at all but a growth hormone secretagogue, included on a different rationale from the other two.
Are the blend components chemically compatible in one vial?
Yes, and the reason can be read from the sequences. None of BPC-157, TB-500, KPV or GHK carries a free cysteine, so the classic co-formulation failure — thiol–disulphide exchange between components — cannot occur. None carries a methionine or tryptophan for the copper to catalyse oxidation of. What they do share is a single formulation, so the pH and buffer suit GHK-Cu first and the others adequately. Checking the residues is how a pairing is judged safe, and it is a check anyone can repeat.
How should a blend be handled after reconstitution?
As its most fragile component dictates, never as the average. A blend inherits the stricter requirement of everything in it: GHK-Cu's sensitivity to chelators and reducing agents, KPV's exposure to surface loss, and the general rule that single-use aliquots beat repeated freezing. A stock that changes colour has lost copper coordination; one that goes hazy has probably started to aggregate. And the concentration on the label is the total — the concentration of any one component is that total multiplied by its measured fraction, which is one more reason the ratio on the certificate is the figure that matters.
All products referenced here are supplied for laboratory and research use only. They are not drugs, foods, supplements or cosmetics, and are not for human or veterinary use.
